Mesoblast (MEOBF) Capital Expenditures (2022 - 2023)
Mesoblast's (MEOBF) quarterly Capital Expenditures came in at $214000.0 in Q2 2023, up 336.73% quarter-over-quarter from $49000.0 in Q1 2022.
Powered by 
Analysis
Mesoblast (MEOBF) Capital Expenditures (2022 - 2023) Analysis & Trends
Mesoblast has disclosed Capital Expenditures across 2 years of filings, most recently posting $214000.0 for Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 3.57 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 648,000.00 |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 5.44 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | -7.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 472,000.00 |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 2.41 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 392,000.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 555,000.00 |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 1.73 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |